Mabwell(SH:688062) Xin Lang Cai Jing·2025-10-10 03:17Core Insights - The stock price of Maiwei Bio has increased by 129.75% year-to-date but has recently experienced a decline of 9.36% over the past five trading days and 14.40% over the past 20 days [2] - The company reported a revenue of 1.01 billion yuan for the first half of 2025, a year-on-year decrease of 12.43%, and a net profit attributable to shareholders of -5.51 billion yuan, down 23.90% year-on-year [2] Company Overview - Maiwei Bio, established on May 12, 2017, and listed on January 18, 2022, is located in the Shanghai Free Trade Zone and specializes in the research, production, and sales of therapeutic biological products [2] - The company's main revenue source is from product sales, accounting for 99.91%, with service provision making up 0.09% [2] - Maiwei Bio operates within the pharmaceutical and biotechnology sector, specifically in chemical pharmaceuticals and formulations, and is involved in concepts such as AI medicine, ophthalmology, and innovative drugs [2] Shareholder and Institutional Holdings - As of June 30, 2025, the number of shareholders for Maiwei Bio increased by 11.66% to 17,900, with an average of 11,379 circulating shares per shareholder, a decrease of 10.44% [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited as the third-largest shareholder with 4.74 million shares, and new entrants such as Xingquan Helun Mixed A and Penghua Medical Technology Stock A [3] - Several funds, including HSBC Jintrust, have exited the top ten circulating shareholders list [3]